We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Test Measures Both T-Cell and Antibody Response to SARS-CoV-2 in Single Blood Sample

By LabMedica International staff writers
Posted on 23 Nov 2021

A newly-developed test can measure both the T-cell and antibody response to SARS-CoV-2 in a single blood sample. More...

The unique approach developed by scientists at Cardiff University (Cardiff, UK) in collaboration with biotechnology company ImmunoServ Ltd. (Wales, UK), can also be used to measure the immune response brought about by vaccination and previous infection. Antibody testing was seen as crucial to easing lockdown during the pandemic – but antibodies are just one arm of the body’s immune response and in some individuals this response is weak and short-lived. Scientists believe T-cell immunity plays a much greater role in protecting people from future infection, however large-scale testing has proven more challenging.

In their study, the researchers took a small sample of blood from individuals of all ages, 68 with underlying cancer and 231 healthy donors. They stimulated T-cells with small pieces of the virus called peptides; the T-cells recognize these peptides if the individual has been previously infected (or vaccinated) and produce chemicals named cytokines which can be easily measured. The study also monitored the size of the T-cell and antibody responses in a group of individuals tested before, during and after the UK’s COVID-19 vaccination campaign. While both vaccine doses were required to maximize the T-cell response against the virus, the study found previously infected individuals required only one dose to achieve comparable immune responses.

The test proved most useful in monitoring immune responses in patients considered more at risk from COVID-19, even after vaccination. The study found the second vaccine dose was essential for cancer patients. Among cancer patients recruited for the study, two doses induced T-cell and antibody responses to equivalent levels as healthy donors. However, it is clear that in some cancer patients there is a dramatic fall of in immune responses at three months, not seen in healthy controls, and highlights the importance of monitoring these responses. The research team will now also monitor whether T-cell and antibody responses induced by vaccination can protect against SARS-CoV-2 mutant variants, including the Delta variant.

“COVID-19 infection rates remain alarmingly high – and it is clear infection even after vaccination is an issue. To help control future outbreaks and identify at-risk individuals, it is important to understand the exact make-up of the immune response to COVID. Our test accurately detects both the T-cell and antibody response to the virus in one blood sample. Together these indicators represent a powerful measure of immunity from COVID-19,” said Dr. Martin Scurr, a research associate at Cardiff University’s School of Medicine and lead author on the study. “The test can be made widely available, is easy to employ and cost effective, and should play a very useful role in monitoring this pandemic, for instance by identifying individuals at greater need of booster jabs.”

Related Links:
Cardiff University 
ImmunoServ Ltd. 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.